|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Xilio Therapeutics, Inc. (XLO) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
26,671,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Xilio Therapeutics is a biotechnology company focused on harnessing the immune system to achieve clinical responses to improve the lives of patients with cancer. Co. is developing a number of tumor-selective, agents through various stages of development. Co.'s product candidates are XTX101, an anti-cytotoxic T-lymphocyte-associated protein 4 monoclonal antibody and XTX202, an interleukin 2 therapy. Co. is also developing its tumor-selective IL-12 product candidate, XTX301 and is focusing on preclinical studies for its tumor-selective IL-15 product candidate, XTX401. Co. has worldwide development and commercialization rights to all of its product candidates.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
106,289 |
106,289 |
1,866,267 |
2,351,517 |
| Total Buy Value |
$72,765 |
$72,765 |
$1,903,142 |
$2,271,932 |
| Total People Bought |
2 |
2 |
3 |
3 |
| Total Buy Transactions |
3 |
3 |
4 |
5 |
| Total Shares Sold |
0 |
8,757 |
8,757 |
13,992 |
| Total Sell Value |
$0 |
$8,615 |
$8,615 |
$12,855 |
| Total People Sold |
0 |
2 |
2 |
3 |
| Total Sell Transactions |
0 |
2 |
2 |
8 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shannon James Samuel |
|
– • – |
2025-06-17 |
4 |
B |
$0.69 |
$17,215 |
D/D |
25,000 |
70,000 |
0.01 |
- |
|
| Shannon James Samuel |
|
– • – |
2025-06-16 |
4 |
B |
$0.69 |
$30,870 |
D/D |
45,000 |
45,000 |
0.01 |
- |
|
| Russo Rene |
PRESIDENT AND CEO |
• • – |
2025-06-16 |
4 |
B |
$0.68 |
$24,680 |
D/D |
36,289 |
281,172 |
0.01 |
- |
|
| Frankenfield Christopher James |
Chief Financial Officer |
• – – |
2025-01-02 |
4 |
AS |
$0.98 |
$6,841 |
D/D |
(6,954) |
12,421 |
|
- |
|
| Brennan Kevin M. |
SVP, FINANCE AND ACCOUNTING |
• – – |
2025-01-02 |
4 |
AS |
$0.98 |
$1,774 |
D/D |
(1,803) |
3,197 |
|
- |
|
| Frankenfield Christopher James |
Chief Financial Officer |
• – – |
2025-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,375 |
19,375 |
|
- |
|
| Luptakova Katarina |
CHIEF MEDICAL OFFICER |
• – – |
2025-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,625 |
16,625 |
|
- |
|
| Russo Rene |
PRESIDENT AND CEO |
• • – |
2025-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
44,250 |
244,883 |
|
- |
|
| Brennan Kevin M. |
SVP, FINANCE AND ACCOUNTING |
• – – |
2025-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Gilead Sciences Inc |
10% Owner |
– – • |
2024-12-18 |
4 |
B |
$1.04 |
$1,830,377 |
D/D |
1,759,978 |
9,105,451 |
2.45 |
- |
|
| Gkcc, Llc |
|
– – • |
2024-06-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,000,000 |
|
- |
|
| Gilead Sciences Inc |
10% Owner |
– – • |
2024-04-02 |
4 |
B |
$0.76 |
$368,790 |
D/D |
485,250 |
7,345,473 |
2.45 |
- |
|
| Gilead Sciences Inc |
10% Owner |
– – • |
2024-03-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,860,223 |
|
- |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2024-02-08 |
4 |
S |
$0.64 |
$171 |
I/I |
(267) |
734,546 |
|
- |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2024-02-08 |
4 |
S |
$0.64 |
$469 |
D/D |
(733) |
2,019,563 |
|
- |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2024-01-12 |
4 |
S |
$0.83 |
$465 |
I/I |
(560) |
734,813 |
|
- |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2024-01-12 |
4 |
S |
$0.83 |
$1,278 |
D/D |
(1,540) |
2,020,296 |
|
- |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2024-01-11 |
4 |
S |
$0.87 |
$495 |
I/I |
(569) |
735,373 |
|
- |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2024-01-11 |
4 |
S |
$0.87 |
$1,362 |
D/D |
(1,566) |
2,021,836 |
|
- |
|
| English Edward C |
Principal Accounting Officer |
• – – |
2022-11-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,002 |
|
- |
|
| Bcip Life Sciences Associates, Lp |
10% Owner |
– – • |
2021-12-10 |
4 |
B |
$9.56 |
$241,202 |
I/I |
25,000 |
2,805,413 |
1.5 |
- |
|
| Bcip Life Sciences Associates, Lp |
10% Owner |
– – • |
2021-12-09 |
4 |
B |
$9.84 |
$39,485 |
I/I |
4,011 |
2,780,413 |
1.5 |
- |
|
| Bcip Life Sciences Associates, Lp |
10% Owner |
– – • |
2021-12-08 |
4 |
B |
$9.62 |
$129,474 |
I/I |
13,458 |
2,776,402 |
1.5 |
- |
|
| Bcip Life Sciences Associates, Lp |
10% Owner |
– – • |
2021-10-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,762,944 |
|
- |
|
| Sv7 (imf) Gp Llp |
10% Owner |
– – • |
2021-10-26 |
4/A |
B |
$16.00 |
$5,000,000 |
I/I |
312,500 |
1,613,632 |
1.5 |
- |
|
52 Records found
|
|
Page 1 of 3 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
